Overview

Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This is a long-term, open-label clinical study designed to enable longer-term treatment of patients completing other clinical studies with intramuscular olanzapine depot. Key objectives of the study are to: - Determine how well intramuscular (IM) olanzapine depot works during long-term treatment, - Evaluate the safety and tolerability of IM olanzapine depot during long-term treatment, - Determine the blood levels of IM olanzapine depot in patients during long-term treatment
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Olanzapine